Ovarian Cancer Research Foundation (OCRF) shared a post on LinkedIn:
“The US Food and Drug Administration (FDA) has approved a new drug combination for people with ovarian, fallopian tube or primary peritoneal cancers who have developed resistance to standard platinum chemotherapy.
The new regime includes the drug relacorilant – Lifyorli – in combination with non-platinum chemotherapy (nab-paclitaxel) which has been proven in Phase 3 clinical trials to improve both progression-free and overall survival.
This is a US regulatory approval and does not automatically apply in Australia. For Australian access, the drug still needs TGA approval.
Other articles about Ovarian Cancer Research Foundation (OCRF) on OncoDaily.